Biotherapeutics drug discovery, much like traditional small molecule drug discovery, starts with validation of the therapeutic target. In many cases validating the target means there is enough data to associate the target to a disease state, and the target can be modulated with a biologic therapeutic.
The early stages of drug discovery are critical and require data-driven breakthroughs, automated workflows to simplify complex analysis to save time and allow scientists to focus in the new biological entity (NBE) discovery and early characterization to enable success during drug development.
Our experts can design your automation needs from nucleic acid isolation to gene expression analysis accoupled with next generation assay platforms allowing for orthogonal hit confirmation using multiple chemistries in a high throughput format, accelerating your path from target ID to lead discovery.
